Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).

doi:10.2174/187152712800672445

Article

Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).

CNS & neurological disorders drug targets - 1 May 2012

Kocabas Neslihan Aygun

Abstract excerpt

Psychiatry is a specialty where the application of pharmacogenomics approaches is made to the study of interindividual differences in response to antidepressants. It is highly applied for improving patient treatment. Major depressive disorder (MDD) is a common and complex disorder resulting from genetic and environmental interactions. Less than 40% of patients with MDD achieve remission, and even after several...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).

Abstract excerpt

Topics

Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD).

Abstract excerpt

Topics

Related research